logo-loader
viewVolitionRx

VolitionRx to present canine cancer detection studies of its Nu.Q Vet Cancer Screening Test at veterinary conference this week

The abstracts cover Nu.Q’s ability to detect lymphoma and hemangiosarcoma, two common canine cancers

Husky and a veterinarian
The lymphoma presentation is scheduled for 1:30 pm ET on Friday, and the hemangiosarcoma presentation is scheduled for 11:15 am ET on Saturday

VolitionRx Limited (NYSEAMERICAN:VNRX) will present a pair of abstracts with study data about its Nu.Q Vet Cancer Screening Test at the 2020 Veterinary Cancer Society (VCS) Virtual Annual Conference. 

The abstracts cover Nu.Q’s ability to detect lymphoma and hemangiosarcoma, two common canine cancers, in studies carried out at Texas A&M University. 

The lymphoma presentation is scheduled for 1:30 pm ET on Friday, and the hemangiosarcoma presentation is scheduled for 11:15 am ET on Saturday. Registration for the conference can be done here.

READ: VolitionRx on the path to launch first commercial products using Nu.Q platform as it ends 2Q with $21.3 million in cash

Currently, dogs suspected of having cancer are often required to undergo multiple diagnostic tests that can be expensive, time consuming and/or painful to the dog, the company said. Conversely, Nu.Q only needs a single blood sample and measures circulating nucleosomes, which are considered an early marker of cancer.

The Texas A&M studies examined 334 blood samples from dogs of varying breed, gender, weight, age and cancer stage. Of these, 134 were health control samples, 134 had lymphoma and 73 had hemangiosarcoma.

"The data demonstrate that the Nu.Q Vet Cancer Screening Test has a high sensitivity and specificity in relation to both Lymphoma and Hemangiosarcoma detection in a large and varied cohort," said Heather Wilson-Robles, chief medical officer of Volition Veterinary Diagnostics Development LLC, and president-elect of VCS. "The results show an Area Under the Curve (AUC) of 87.3% and 97.6%, respectively, for Lymphoma and Hemangiosarcoma.

Cancer is the most common cause of death among dogs over the age of two and up to half of all drops over the age of 10 develop cancer at some point in their life, the company said. Lymphoma and hemangiosarcoma make up roughly one-third of canine cancers.

"These positive findings provide us with real confidence as we move forward towards the launch of our first product, the Nu.Q Vet Cancer Screening Test, anticipated in the coming weeks,” Wilson-Robles said. “Early diagnosis has a huge potential to help improve the treatment and the quality of life for dogs as well as providing valuable additional information to inform the clinical decision-making process."

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: VolitionRx

Price: 3.26 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $156.22 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

VolitionRx hosts virtual capital markets day event to discuss upcoming...

VolitionRx Limited (NYSE AMERICAN: VNRX) CEO Cameron Reynolds the Austin, Texas-based epigenetics company hosted a virtual capital markets day event on Tuesday, October 20, 2020. Reynolds says the presentation focused on new data, and the launch and commercial roll out of the company's first...

4 days, 12 hours ago

2 min read